Market Place
Sourcing Support
Faron Pharma Ltd: Director Dealing Update
31 Mar 2026 //
PHARMIWEB
Faron Pharma Appoints New CTO For Late-Stage Development
26 Mar 2026 //
PHARMIWEB
Faron Pharma: Extraordinary General Meeting Results
02 Mar 2026 //
PHARMIWEB
Faron, City Of Hope Developing Phase II Trial For Bexmarilimab
02 Mar 2026 //
PHARMIWEB
Faron Secures Bexmarilimab Poster at BSH 2026 Meeting
23 Feb 2026 //
PHARMIWEB
Immunotherapy Review Spotlights Clever-1 Inhibition
29 Jan 2026 //
PHARMIWEB
Faron Expands Bexmarilimab Program With Phase I/II Trial
27 Jan 2026 //
ACCESSWIRE
Faron Collaborates With Institute For Cancer Research On BLAZE
22 Dec 2025 //
PHARMIWEB
Faron Pharma Announces Nomination Board Composition
17 Dec 2025 //
PHARMIWEB
Faron`s 2026 Financial Calendar
27 Nov 2025 //
PHARMIWEB
Faron Reveals 2 Bexmarilimab Abstracts Accepted At ASH 2025
04 Nov 2025 //
PHARMIWEB
Faron Advances Bexmab To FDA Registrational Trial Post Phase 2
03 Nov 2025 //
PHARMIWEB
BEXMAB Ph1/2 Data at ESMO 2025 Strengthens Bexmarilimab Profile
20 Oct 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd Reports Half-Year Financial Results
27 Aug 2025 //
PHARMAWEB
Faron`s Bexmarilimab Studies Accepted for Oral Presentation
09 Jul 2025 //
ACCESSWIRE
Faron Pharmaceuticals updates Phase II data at EHA 2025
12 Jun 2025 //
ACCESSWIRE
Faron Pharmaceuticals Presents Phase II Data at ASCO 2025
02 Jun 2025 //
ACCESSWIRE
Faron Publishes Phase I BEXMAB Study Data in Lancet Haematology
30 May 2025 //
ACCESSWIRE
Faron`s Bexmarilimab Shows Potential in Myeloid Malignancies
27 May 2025 //
ACCESSWIRE
Faron Reveals New Data on Bexmarilimab for Cancer Patients
23 May 2025 //
ACCESSWIRE
Faron Appoints Ralph Hughes as Chief Business Officer (CBO)
21 May 2025 //
ACCESSWIRE
Faron Accepts Bexmarilimab Data for EHA 2025 Congress
15 May 2025 //
ACCESSWIRE
Faron`s Acceptance of Bexmarilimab Ph II Data for ASCO 2025
24 Apr 2025 //
ACCESSWIRE
Faron Reports Positive Phase 2 Results in Myelodysplastic Syndrome
15 Apr 2025 //
ACCESSWIRE
Faron to Present Bexmarilimab Data at 2025 MDS Foundation Congress
27 Mar 2025 //
ACCESSWIRE
Results of the Annual General Meeting, Change of Directors
21 Mar 2025 //
ACCESSWIRE
Shareholders` Board Updates Proposal On Member Elections
20 Mar 2025 //
ACCESSWIRE
Faron`s bexmarilimab Developers Named European Inventor Award Finalists
16 May 2024 //
GLOBENEWSWIRE
Faron to Host Webcast to Discuss data from Phase 1 of Study of Bexmarilimab
14 Mar 2024 //
GLOBENEWSWIRE
Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab
09 Jan 2024 //
GLOBENEWSWIRE
Faron Announces Publication of Full Analysis from Phase 1/2 of Bexmarilimab
07 Dec 2023 //
GLOBENEWSWIRE
Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
06 Nov 2023 //
GLOBENEWSWIRE
Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab
02 Nov 2023 //
GLOBENEWSWIRE
Faron to Host Webcast to Discuss Data From Phase I/II Study of Bexmarilimab
02 Oct 2023 //
GLOBENEWSWIRE
